老年涎腺癌患者放疗疗效:大型多中心分析
该多中心分析纳入2005至2020年间三家三级癌症中心接受(化)放疗的288例≥65岁原发性涎腺癌患者,中位局部/区域控制(LRC)、无进展生存(PFS)和总生存(OS)分别为113、39和75个月。年龄、体能状态、合并症、根治性与辅助治疗、局部晚期及远处转移与较差结局相关;碳离子 boost 的剂量递增放疗改善LRC但未改善PFS或OS;同步化疗未改善结局;3级急性和慢性毒性发生率分别为24.3%和16.7%,未观察到4/5级毒性。
要点
- 老年涎腺癌(化)放疗后中位LRC 113个月、PFS 39个月、OS 75个月。
- 碳离子boost剂量递增(总剂量>70 GyEQD2)改善LRC,但未改善PFS或OS。
- 同步化疗未改善老年涎腺癌患者治疗结局。
核心结论
- 老年涎腺癌患者接受(化)放疗可获得良好的局部/区域控制和可耐受的毒性。
- 治疗决策应基于患者体能状态而非实际年龄。
研究设计与样本
- 多中心回顾性分析,纳入2005至2020年三家三级癌症中心接受(化)放疗的288例≥65岁原发性涎腺癌患者。
主要发现
- 中位LRC、PFS和OS分别为113、39和75个月。
- 年龄、体能状态、合并症、根治性与辅助(化)放疗、局部/区域晚期及远处转移与较差结局相关。
- 碳离子boost剂量递增放疗(总剂量>70 GyEQD2)改善LRC,但未改善PFS或OS。
- 同步放化疗未改善治疗结局。
- 3级急性毒性和慢性毒性分别见于70例(24.3%)和48例(16.7%),未观察到4/5级毒性。
关键数值与推荐
- 剂量递增放疗定义为总剂量>70 GyEQD2并联合碳离子boost。
- 3级急性毒性发生率为24.3%(70例),3级慢性毒性发生率为16.7%(48例)。
临床怎么用
- 对老年涎腺癌患者制定治疗决策时应评估体能状态而非仅依据年龄。
- 碳离子boost剂量递增可用于改善局部/区域控制,但需权衡未改善生存的预期。
- 同步化疗在老年涎腺癌患者中未显示结局获益,选择时应谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate oncological outcomes and treatment-related toxicities of elderly salivary gland cancer patients undergoing (chemo)radiotherapy. MATERIAL AND METHODS: Local/locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) of elderly patients ≥ 65 years with primary salivary gland cancers undergoing (chemo)radiotherapy between 2005 and 2020 at three tertiary cancer centers were calculated. The impact of clinicopathological and treatment parameters on outcomes were analyzed, and acute and chronic toxicities were quantified. RESULTS: 288 elderly salivary gland cancer patients were included in this multicenter analysis, and their median LRC, PFS and OS amounted to 113, 39 and 75 months, respectively. Age, performance status, comorbidities, definitive vs. adjuvant (chemo)radiotherapy as well as locally/locoregionally advanced cancers and distant metastases correlated with reduced outcomes in elderly salivary gland patients. Patients receiving dose-escalated radiotherapy (total doses > 70 GyEQD2) with carbon ion boost radiation resulted in improved LRC, but no improvements in PFS or OS. Concomitant chemoradiotherapy did not improve treatment outcomes in elderly salivary gland carcinoma patients. Radiotherapy of elderly salivary gland cancer patients resulted in moderate higher-grade toxicities despite dose escalation with 70 (24.3%) and 48 patients (16.7%) experiencing acute and chronic grade 3 toxicities, respectively. No grade 4/5 toxicities were observed in this patient cohort. CONCLUSION: Data from the largest multicenter analysis of elderly salivary gland cancer patients undergoing (chemo)radiotherapy demonstrate favorable LRC and tolerable toxicity rates. Decision-making for these vulnerable patients should be based on patient performance rather than chronological patient age.
引用
- Akbaba S, Rühle A, Rothhaar S, et al. Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - Results from a large multicenter analysis. Radiother Oncol. 2020. PMID: 33359662. doi:10.1016/j.radonc.2020.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。